Table 3.
Bivariate Odds of Substitution of Azacitidine or Decitabine in Total and by Age and Primary Status
| Section 1: Use of Azacitabine or Decitabine within 30 Days following Diagnosis as Outpatient | |||||||
|---|---|---|---|---|---|---|---|
| Variables | (1) | (2) | (3) | (4) | (5) | (6) | (7) |
| Full Sample OR (95% CI) | First Primaryc OR (95% CI) | Not Firstd OR (95% CI) | First Primaryc Age 65–69 OR (95% CI) | First Primaryc Age 70–74 OR (95% CI) | Not Firstd Age 65–69 OR (95% CI) | Not Firstd Age 70–74 OR (95% CI) | |
| Major (Q1)a | 1.751** | 1.574 | 1.604 | 1.200 | 2.169* | 2.202 | 1.105 |
| (1.006–3.047) | (0.645–3.840) | (0.777–3.312) | (0.394–3.651) | (0.879–5.351) | (0.648–7.484) | (0.436–2.801) | |
| Moderate (Q2‐4)b | 1.544** | 1.559 | 1.265 | 1.023 | 2.033** | 1.835 | 1.569* |
| (1.069–2.230) | (0.877–2.772) | (0.777–2.060) | (0.469–2.230) | (1.158–3.569) | (0.779–4.322) | (0.920–2.677) | |
| Observations | 1,568 | 964 | 604 | 410 | 551 | 218 | 329 |
| Section 2: Use of Azacitabine or Decitabine within 60 Days following Diagnosis as Outpatiente | |||||||
|---|---|---|---|---|---|---|---|
| Major (Q1)a | 1.531* | 1.621 | 1.276 | 1.204 | 2.140* | 1.655 | 1.190 |
| (0.946–2.478) | (0.811–3.242) | (0.648–2.513) | (0.396–3.664) | (0.868–5.275) | (0.558–4.907) | (0.493–2.872) | |
| Moderate (Q2–4)b | 1.636*** | 1.531* | 1.478* | 1.027 | 2.006** | 1.489 | 1.468 |
| (1.210–2.213) | (0.976–2.402) | (0.973–2.245) | (0.471–2.238) | (1.144–3.518) | (0.687–3.226) | (0.884–2.437) | |
| Observations | 1,568 | 964 | 604 | 411 | 553 | 243 | 361 |
| Section 3: Use of Azacitabine or Decitabine within 30 to 60 Days as Outpatient in Patients Not Receiving Either Drug Prior to Diagnosis | ||
|---|---|---|
| Variables | (1) | (2) |
| Full Sample within 30‐day post, not pre OR (95% CI) | Full Sample within 60‐day post, not pre OR (95% CI) | |
| Major (Q1)a | 1.857** | 1.620* |
| (1.032–3.344) | (0.980–2.680) | |
| Moderate (Q2–4)b | 1.543** | 1.643*** |
| (1.036–2.299) | (1.193–2.262) | |
| Observations | 1,484 | 1,484 |
a
Major Shortage‐first quarter 2011 as compared to 2008, quarter 1 through 2010 quarter 4.
b
Moderate Shortage‐ quarters 2–4, 2011 as compared to 2008, quarter 1 through 2010 quarter 4.
c
First Primary describes subgroup of patients in which AML was first primary cancer.
d
Not First describes subgroup of patients in which AML was Not a patient's first primary cancer.
e
HCPCS (Centers for Medicare and Medicaid Services [CMS] 2018) codes used to identify Azacitidine is J9025 and Decitibine J0894 respectively.
Robust 95% confidence intervals show in exponential form in parentheses.
***p < .01, **p < .05, *p < .1.